On August 11, 2020, the U.S. Court of Appeals for the Ninth Circuit decisively reversed the Federal Trade Commission’s (FTC or Commission) controversial district court win challenging Qualcomm’s licensing practices. In...more
8/18/2020
/ Anticompetitive Behavior ,
Antitrust Violations ,
Appeals ,
Cell Phones ,
Corporate Counsel ,
Federal Trade Commission (FTC) ,
FRAND ,
FTC Act ,
Injunctive Relief ,
Intellectual Property Protection ,
IP License ,
Lack of Evidence ,
Monopolization ,
OEM ,
Patent Royalties ,
Qualcomm ,
Remand ,
Reversal ,
Sherman Act ,
Standard Essential Patents
On April 22, 2020, the Third Circuit Court of Appeals vacated and remanded an order certifying a class of direct purchaser plaintiffs in In re: Lamictal Direct Purchaser Antitrust Litigation, holding that the district court...more
4/30/2020
/ Antitrust Injuries ,
Antitrust Litigation ,
Appeals ,
Burden of Proof ,
Class Certification ,
Delays ,
Direct Purchasers ,
FRCP 23 ,
FRCP 23(b)(3) ,
Generic Drugs ,
Manufacturers ,
Pharmaceutical Industry ,
Predominance Requirement ,
Remand ,
Reverse Payment Settlement Agreements ,
Vacated ,
Wholesale
On February 25, 2019, in FTC v. Shire ViroPharma, Inc., the U.S. Court of Appeals for the Third Circuit confirmed that the Federal Trade Commission (FTC) cannot plead its way into federal court via Section 13(b) of the FTC...more
3/2/2019
/ Administrative Proceedings ,
Administrative Remedies ,
Anti-Competitive ,
Antitrust Violations ,
Appeals ,
Disgorgement ,
Dismissals ,
Federal Pleading Requirements ,
Federal Trade Commission (FTC) ,
FTC Act ,
Generic Drugs ,
Illegal Profits ,
Injunctive Relief ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Remedies ,
Restitution ,
Unfair Competition